Treatment
Stem cell therapy for neuropathy: what’s proven, what’s not
Clinics advertise stem cell and “exosome” injections for nerve damage, often for five figures and always up front. Here is what the FDA has actually approved, what is genuinely being tested, and the questions that separate a trial from a sales pitch.
Written by the Managing Neuropathy editorial team under the direction of Dr. Tom Biernacki, DPM, FACFAS · Clinical review pending · Last updated 25 September 2026
The short answer. There is no FDA-approved stem cell treatment for peripheral neuropathy. The only approved stem cell products are blood-forming cells from umbilical cord blood, and they are approved for disorders of blood production, not for nerves. The FDA has warned publicly that unapproved stem cell and exosome products have caused blindness, tumors and life-threatening infections. Research is ongoing and some of it is serious, but a clinic that asks you to pay for treatment is not doing research.
What clinics sell
The offers vary, but the shape is consistent: an injection or infusion of cells said to come from umbilical cord tissue, amniotic fluid, your own bone marrow or your own fat, or a product marketed as containing exosomes, which are small vesicles released by cells. The pitch is regeneration — that the cells will repair damaged nerves. Payment is usually a package, in full, before treatment, and it is always out of pocket, because nothing in this category is approved for neuropathy and therefore nothing is covered.
The marketing pattern is familiar from every other unproven neuropathy product: testimonials instead of trials, a mechanism that sounds like a mechanism, and no interest in establishing your cause first. How to read a sales page.
What the FDA actually says
The FDA’s position is unusually direct, and it is worth reading before you read a clinic’s brochure.
- What is approved: blood-forming stem cells, also called hematopoietic progenitor cells, derived from umbilical cord blood. They are approved for disorders affecting the production of blood, and nothing else.
- What is not: the FDA states that none of these products have been approved to treat any neurological disorder, and lists multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, epilepsy and stroke as examples. Peripheral neuropathy is not on the approved list either.
- Exosomes: the FDA has stated plainly that there are currently no FDA-approved exosome products, in a 2019 public safety alert prompted by serious adverse events in patients treated with unapproved exosome products in Nebraska.
- The harms are specific. The FDA names blindness, tumor formation, bacterial infections including life-threatening blood infections, cells migrating to places they were not intended to go, and the failure to receive an approved treatment that might have worked.
What is genuinely being tested
Real research does exist, and it is early. Checked on ClinicalTrials.gov on 20 September 2026, the recruiting studies in this space included a phase 2 randomized controlled trial of umbilical cord mesenchymal stem cells for moderate to severe diabetic peripheral neuropathy, and an early-phase study of a cell therapy in Charcot-Marie-Tooth disease type 1A. Those are the kind of studies that eventually answer the question.
The same search also returns open-ended “treatment studies” run by private clinics, with no assigned phase and broad lists of conditions. A registration on ClinicalTrials.gov is not an FDA approval and not a quality mark: sponsors register their own studies, and some listed studies charge participants to take part. If a clinic points at its ClinicalTrials.gov listing as evidence, that listing is the beginning of the check, not the end of it.
Costs, and the risks that come with them
Because nothing here is approved for neuropathy, insurance does not cover it, and packages are paid in advance. The financial risk is obvious. The clinical risks are the ones the FDA lists above, plus two that are easy to overlook: an injection into a foot or leg with reduced sensation and, in diabetes, impaired healing is a genuine infection risk, and time spent on an unproven treatment is time not spent finding a cause that might be treatable.
If a foot injection site becomes red, warm, swollen or starts to drain — particularly if you have diabetes or numb feet — treat it as urgent and get it seen the same day.
Questions to ask any clinic
The answer is no. What matters is whether they say so plainly.
The FDA tells patients to ask for it. A legitimate research program has one and will give it to you.
Charging patients for an experimental treatment is a red flag, not a normal cost of research.
Contamination with bacteria, viruses or mold is among the harms the FDA has documented.
If nobody checked glucose tolerance, B12, thyroid and kidney function, the treatment is not aimed at anything in particular.
Ask about refunds and about what the follow-up plan is, in writing, before paying.
What has better evidence
The unglamorous list is also the one with trials behind it: find and treat the cause, control glucose, blood pressure and cholesterol, treat the pain properly, train balance, and protect the feet from injuries they cannot feel. Treatments sorted by what they actually do. And if the appeal of stem cells is the promise of repair, the honest version of that conversation is here: what genuinely recovers, and how long nerves take.
Common questions
Is stem cell therapy approved for neuropathy?
No. The only FDA-approved stem cell products are blood-forming cells from umbilical cord blood, approved for disorders of blood production. The FDA states that none of these products are approved to treat neurological disorders.
Are exosome injections safe?
There are no FDA-approved exosome products. The agency issued a public safety alert in 2019 after serious adverse events in patients given unapproved exosome products, and warns that these products can be contaminated.
But there are clinical trials — doesn’t that mean it works?
It means the question is being studied. Early-phase and phase 2 trials are how a treatment earns its evidence; they are not evidence in themselves. Registration on ClinicalTrials.gov is self-submitted and is not an FDA endorsement.
What does it cost?
It is always out of pocket, because no product in this category is approved for neuropathy. Packages are typically paid in advance, which puts all the financial risk on you.
Is it worth trying if nothing else has helped?
That feeling is understandable, and it is exactly what this market is built on. Before spending, make sure a complete workup has been done, that pain is being treated properly and that balance and foot protection are in place — those change outcomes, and they are the ones with evidence.
Related reading
Neuropathy treatment, sorted by what it does · Can neuropathy be reversed? · The “reverse it in 7 days” claim · Red light therapy · Supplements for neuropathy
Sources and further reading: FDA, important patient and consumer information about regenerative medicine therapies, for what is approved and the harms reported from unapproved products. FDA, consumer alert on regenerative medicine products including stem cells and exosomes, for the statement that none are approved for neurological disorders. FDA public safety alert on unapproved stem cell and exosome products (2019). ClinicalTrials.gov, searched 20 September 2026 for recruiting stem cell studies in peripheral neuropathy.
This page is general education and is not a diagnosis, a treatment plan, or advice about a specific clinic or product. Clinical review by Dr. Biernacki is pending; the review date will be shown here once complete.
For our Michigan neighbors
Considering a
five-figure package?
A second opinion costs a fraction of that, and it starts with what is actually driving your neuropathy. Dr. Biernacki’s Michigan practice can give you one.
Everywhere else, take this page to your own clinician.
Dr. Tom Biernacki, DPM, FACFAS is a double board-certified foot and ankle surgeon (ABFAS and ABPM) and a Fellow of the American College of Foot & Ankle Surgeons. He is the founder of Balance Foot & Ankle in Howell and Bloomfield Township, Michigan, where peripheral neuropathy, diabetic foot risk and loss of protective sensation are part of his weekly clinic. His patient education videos have drawn more than 950,000 subscribers on YouTube. Managing Neuropathy is written by its editorial team under his direction, to put the explanation he gives in the exam room in front of the people who cannot get to one — including when a product is worth buying and when it is not.